<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00623259</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-MAG-001</org_study_id>
    <nct_id>NCT00623259</nct_id>
  </id_info>
  <brief_title>Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects</brief_title>
  <official_title>Phase I Vaccination Study Testing the Safety and Reactogenicity of a Recombinant MVA HIV Multiantigen Vaccine (MVA-mBN120B) in HIV-infected Subjects With CD4 Count &gt; 350/µL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bavarian Nordic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monocentric study to assess the safety and immunogenicity of the recombinant MVA-HIV&#xD;
      multiantigen vaccine MVA-mBN120B in HIV-infected subjects. 15 subjects will receive&#xD;
      immunizations at day 0, after 4 and 12 weeks at a dose of 2E8 TCID50 MVA-mBN120B. The vaccine&#xD;
      will be administered subcutaneously.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-mBN120B</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects aged between 18 to 55 years.&#xD;
&#xD;
          -  HIV-1 infection documented by either plasma HIV-1 RT-PCR or bDNA assay at any time&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Stable on HAART with regard to immunologic and clinical parameters for at least 6&#xD;
             consecutive months prior to study entry (substitutions of one drug for another in the&#xD;
             same class due to reasons other than virologic failure are allowed).&#xD;
&#xD;
          -  Plasma HIV RNA level &lt; 50 copies/ml for at least 6 months prior to study entry; single&#xD;
             blips of up to 400 HIV-1 RNA copies/ml are acceptable if they resolve spontaneously&#xD;
             without a change in HAART.&#xD;
&#xD;
          -  Plasma HIV-1 RNA levels of &lt; 50 copies/ml at study entry.&#xD;
&#xD;
          -  Women with childbearing potential must have a negative serum pregnancy test at&#xD;
             screening and a negative urine pregnancy test within 24 hours prior to immunization.&#xD;
&#xD;
          -  Women of childbearing potential must have used an acceptable method of contraception&#xD;
             for 30 days prior to the first immunization, must agree to use an acceptable method of&#xD;
             contraception during the study, and must not become pregnant for at least 28 days&#xD;
             after the last immunization. A woman is considered of childbearing potential unless&#xD;
             post-menopausal or surgically sterilized. (Acceptable contraception methods are&#xD;
             restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices&#xD;
             or licensed hormonal products.)&#xD;
&#xD;
          -  CD4 cells ≥ 350/µl (two determinations, of which one must be done during the screening&#xD;
             and the other must be done within 3 months before study entry)&#xD;
&#xD;
          -  CD4 nadir &gt; 150/µl.&#xD;
&#xD;
          -  Troponin I within normal institutional limits.&#xD;
&#xD;
          -  White blood cells ≥ 2500/mm3 and &lt; = 11,000/ mm3.&#xD;
&#xD;
          -  Negative urine glucose by dipstick or urinalysis at screening.&#xD;
&#xD;
          -  Haemoglobin ≥ 9.0g/dL.&#xD;
&#xD;
          -  Platelets ≥ 100,000/mm3&#xD;
&#xD;
          -  Adequate renal function defined as:&#xD;
&#xD;
               1. Calculated Creatinine clearance (CrCl) &gt; 50 mL/min as estimated by the&#xD;
                  Cockroft-Gault equation.&#xD;
&#xD;
               2. Urine protein &lt; = 100 mg/dL or none or trace proteinuria (by urinalysis or dip&#xD;
                  stick (&lt; = 2+ proteinuria)).&#xD;
&#xD;
          -  Adequate hepatic function defined as:&#xD;
&#xD;
               1. Total bilirubin &lt; = 2 x ULN unless elevation is explained by antiviral therapy&#xD;
                  and in the absence of other evidence of significant liver disease (healthy&#xD;
                  subjects without clinical disease with Gilbert's Syndrome can be included).&#xD;
&#xD;
               2. AST (SGOT), ALT (SGPT) and alkaline phosphatase &lt; = 3 x ULN without clinically&#xD;
                  significant findings.&#xD;
&#xD;
          -  Electrocardiogram (ECG) without abnormal findings (e.g. any kind of atrioventricular&#xD;
             or intraventricular conditions or blocks such as complete left or right bundle branch&#xD;
             block, AV-node block, QTc or PR prolongation, premature atrial contractions or other&#xD;
             atrial arrhythmia, sustained ventricular arrhythmia, two premature ventricular&#xD;
             contractions (PVC) in a row, ST elevation consistent with ischemia).&#xD;
&#xD;
          -  Negative test for hepatitis B surface Antigen (HBsAg) and hepatitis C antibody (HCV&#xD;
             Ab).&#xD;
&#xD;
          -  Free of obvious health problems as established by medical history and physical&#xD;
             examination before entering into the study.&#xD;
&#xD;
          -  Signed informed consent form of the subject after information of the risks and&#xD;
             benefits of the study in a language the subject clearly understands, and before any&#xD;
             study specific procedure.&#xD;
&#xD;
          -  Availability for follow-up for the planned duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  Uncontrolled serious infection i.e. not responding to antimicrobial therapy.&#xD;
&#xD;
          -  History of any serious medical condition, which in the opinion of the investigator&#xD;
             would compromise the safety of the subject.&#xD;
&#xD;
          -  History of suspected or active autoimmune disease. Persons with vitiligo or thyroid&#xD;
             disease taking thyroid replacement therapy are not excluded.&#xD;
&#xD;
          -  History of chronic alcohol abuse (40g / day for at least 6 months) and/or intravenous&#xD;
             drug abuse (within the past 6 months).&#xD;
&#xD;
          -  History of malignancy, other than squamous cell or basal cell skin cancer, unless&#xD;
             there has been surgical excision that is considered to have achieved cure. Subjects&#xD;
             with history of skin cancer at the vaccination site are excluded.&#xD;
&#xD;
          -  Manifestation of clinically significant and severe haematological, pulmonary, central&#xD;
             nervous, cardiovascular or gastrointestinal disorder.&#xD;
&#xD;
          -  Clinically significant mental disorder not adequately controlled by medical treatment.&#xD;
&#xD;
          -  Any condition which might interfere with study objectives or would limit the subject's&#xD;
             ability to complete the study or to be compliant in the opinion of the investigator.&#xD;
&#xD;
          -  History of coronary heart disease, myocardial infarction, angina, congestive heart&#xD;
             failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood&#xD;
             pressure, or any other heart condition under the care of a doctor.&#xD;
&#xD;
          -  History of an immediate family member (father, mother, brother, or sister) who died&#xD;
             due to ischemic heart disease before age 50 years.&#xD;
&#xD;
          -  Ten percent or greater risk of developing a myocardial infarction or coronary death&#xD;
             within the next 10 years using the National Cholesterol Education Program's risk&#xD;
             assessment tool. (http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof) NOTE:&#xD;
             This criterion applies only to volunteers 20 years of age and older.&#xD;
&#xD;
          -  History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccine.&#xD;
&#xD;
          -  Known allergy to egg or aminoglycoside (gentamicin).&#xD;
&#xD;
          -  History of anaphylaxis or severe allergic reaction.&#xD;
&#xD;
          -  Having received any vaccinations or planned vaccinations with a live vaccine within 30&#xD;
             days prior or after study vaccination.&#xD;
&#xD;
          -  Having received any vaccinations or planned vaccinations with a killed vaccine&#xD;
             within14 days prior or after study vaccination.&#xD;
&#xD;
          -  Chronic administration (defined as more than 14 days) of systemic immuno-suppressant&#xD;
             drugs during a period starting from six months prior to administration of the vaccine&#xD;
             and ending at study conclusion. (Corticosteroid nasal sprays are permissible. Persons&#xD;
             who have used topical and inhaled steroids can be enrolled after their therapy is&#xD;
             completed).&#xD;
&#xD;
          -  Post organ transplant subjects whether or not receiving chronic immunosuppressive&#xD;
             therapy.&#xD;
&#xD;
          -  Any continuous therapy that may influence CD4 counts other than antiretroviral&#xD;
             therapy.&#xD;
&#xD;
          -  Administration or planned administration of immunoglobulins and/or any blood products&#xD;
             during a period starting from 3 months prior to administration of the vaccine and&#xD;
             ending at study conclusion.&#xD;
&#xD;
          -  Use of any investigational or non-registered drug or vaccine other than the study&#xD;
             vaccine within 30 days or 7 half-lives (whichever is longer) preceding the first dose&#xD;
             of the study vaccine, or planned administration of such a drug during the study&#xD;
             period.&#xD;
&#xD;
          -  Previous participation in another HIV vaccination study.&#xD;
&#xD;
          -  Previous participation in any MVA vaccination study during the last 5 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2008</study_first_posted>
  <last_update_submitted>May 19, 2010</last_update_submitted>
  <last_update_submitted_qc>May 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Monika Fluer</name_title>
    <organization>Bavarian Nordic</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

